BAJAJ BROKING

open-demat-imgOpen Demat
Login-imgLoginopens in a new tab
be-a-partner-imgBe a Partner
samadhan-imgSamadhanopens in a new tab
open-demat-imgOpen Demat
InstallInstall App
Download AppInstall App
Notification
Divine Hira Jewellers IPO is Open!
Apply for the Divine Hira Jewellers IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
Trade Nowopens in a new tab
framedot
img
sun pharmaceutical ind l stock

Sun Pharmaceutical Ind L Share Price

₹ 1738 33.69 (1.97%)
Mar 18 2025 02:06 PM Pharmaceuticals NSE: SUNPHARMA

Sun Pharmaceutical Ind L Share Price Update

As of the latest trading session, Sun Pharmaceutical Ind L share price is currently at 1738, which is up by 33.69 from its previous closing. Today, the stock has fluctuated between 1700.00 and 1739.35. Over the past year, Sun Pharmaceutical Ind L has achieved a return of 8.46 %. In the last month alone, the return has been -0.57 %. Read More...

Sun Pharmaceutical Ind L Performance

Day Range

Low1700.00 High1739.35
1736.40

52 Week Range

Low 1377.20 High 1960.35
1736.40

Sun Pharmaceutical Ind L Share Price

3351

524715

SUNPHARMA

img img img img
Compare to down-arrow
View down-arrow
Display down-arrow
Studies down-arrow
No Data Available

Open Price

1714.35

Prev. Close

1704.30

Volume (Shares)

1635002.00

Total traded value

28390.17

Upper Circuit

1874.70

Lower Circuit

1533.90

Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.

Sun Pharmaceutical Ind L Fundamentals


(Standalone)

Market Cap (Cr) 417004.40
PE Ratio (TTM) 129.94
Book Value / Share 98.33
Beta 0.58
ROE 12.05%
EPS (TTM) 13.13
Dividend Yield 0.79%
Net Profit Qtr (Cr) 1181.05

Sun Pharmaceutical Ind L Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 5985.33
Operating Expense 4995.27
Net Profit 1181.05
Net Profit Margin (%) 19.73
Earnings Per Share (EPS) 4.90
EBITDA 1771.86
Effective Tax Rate (%) 6.63
Particulars SEP 2024 (Values in Cr)
Revenue 5123.67
Operating Expense 4318.37
Net Profit 863.29
Net Profit Margin (%) 16.84
Earnings Per Share (EPS) 3.60
EBITDA 1424.91
Effective Tax Rate (%) 3.61
Particulars JUN 2024 (Values in Cr)
Revenue 4409.74
Operating Expense 4322.89
Net Profit 237.82
Net Profit Margin (%) 5.39
Earnings Per Share (EPS) 1.00
EBITDA 843.81
Effective Tax Rate (%) 7.79
Particulars MAR 2024 (Values in Cr)
Revenue 5536.99
Operating Expense 4356.24
Net Profit 867.60
Net Profit Margin (%) 15.66
Earnings Per Share (EPS) 3.60
EBITDA 2012.40
Effective Tax Rate (%) 38.10
Particulars DEC 2023 (Values in Cr)
Revenue 4903.66
Operating Expense 4329.27
Net Profit 721.31
Net Profit Margin (%) 14.70
Earnings Per Share (EPS) 3.00
EBITDA 1365.99
Effective Tax Rate (%) 4.01
Particulars MAR 2024 (Values in Cr)
Revenue 19843.53
Operating Expense 17072.26
Net Profit 2858.18
Net Profit Margin (%) 14.40
Earnings Per Share (EPS) 11.90
EBITDA 5834.35
Effective Tax Rate (%) 17.14
Particulars MAR 2023 (Values in Cr)
Revenue 20394.63
Operating Expense 16412.32
Net Profit 1690.72
Net Profit Margin (%) 8.29
Earnings Per Share (EPS) 7.00
EBITDA 3814.10
Effective Tax Rate (%) 2.89
Particulars MAR 2022 (Values in Cr)
Revenue 15518.50
Operating Expense 14416.51
Net Profit -99.99
Net Profit Margin (%) -0.64
Earnings Per Share (EPS) -0.40
EBITDA 2044.91
Effective Tax Rate (%) 132.58
Particulars MAR 2021 (Values in Cr)
Revenue 13988.40
Operating Expense 13362.99
Net Profit 842.40
Net Profit Margin (%) 6.02
Earnings Per Share (EPS) 3.50
EBITDA 2359.52
Effective Tax Rate (%) 1.53
Particulars MAR 2020 (Values in Cr)
Revenue 11906.74
Operating Expense 10789.85
Net Profit 3211.14
Net Profit Margin (%) 26.96
Earnings Per Share (EPS) 13.38
EBITDA 4222.57
Effective Tax Rate (%) 1.28
Particulars MAR 2024 (Values in Cr)
Book Value / Share 265.36
ROE % 16.13
ROCE % 17.20
Total Debt to Total Equity 0.08
EBITDA Margin 28.63
Particulars MAR 2023 (Values in Cr)
Book Value / Share 233.38
ROE % 16.46
ROCE % 16.79
Total Debt to Total Equity 0.08
EBITDA Margin 27.59
Particulars MAR 2022 (Values in Cr)
Book Value / Share 200.11
ROE % 14.50
ROCE % 17.97
Total Debt to Total Equity 0.05
EBITDA Margin 29.19
Particulars MAR 2021 (Values in Cr)
Book Value / Share 193.65
ROE % 11.14
ROCE % 13.60
Total Debt to Total Equity 0.13
EBITDA Margin 27.80
Particulars MAR 2020 (Values in Cr)
Book Value / Share 188.66
ROE % 9.66
ROCE % 9.85
Total Debt to Total Equity 0.22
EBITDA Margin 22.43
Particulars MAR 2024 (Values in Cr)
Book Value / Share 98.76
ROE % 12.05
ROCE % 12.22
Total Debt to Total Equity 0.40
EBITDA Margin 28.78
Particulars MAR 2023 (Values in Cr)
Book Value / Share 98.98
ROE % 13.89
ROCE % 16.26
Total Debt to Total Equity 0.27
EBITDA Margin 32.43
Particulars MAR 2022 (Values in Cr)
Book Value / Share 102.48
ROE % -5.19
ROCE % 7.47
Total Debt to Total Equity 0.24
EBITDA Margin 24.56
Particulars MAR 2021 (Values in Cr)
Book Value / Share 112.28
ROE % 3.53
ROCE % 3.57
Total Debt to Total Equity 0.27
EBITDA Margin 17.35
Particulars MAR 2020 (Values in Cr)
Book Value / Share 101.68
ROE % 13.60
ROCE % 11.85
Total Debt to Total Equity 0.27
EBITDA Margin 33.69
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 10520.68
Total Assets 85462.88
Total Liabilities 85462.88
Total Equity 67105.97
Share Outstanding 2399334970
Price to Book Ratio 16.41
Return on Assets (%) 11.20
Return on Capital (%) 13.69
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 5770.29
Total Assets 80743.59
Total Liabilities 80743.59
Total Equity 59315.47
Share Outstanding 2399334970
Price to Book Ratio 9.93
Return on Assets (%) 10.49
Return on Capital (%) 12.93
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 5033.35
Total Assets 69807.77
Total Liabilities 69807.77
Total Equity 51066.11
Share Outstanding 2399334970
Price to Book Ratio 8.93
Return on Assets (%) 4.68
Return on Capital (%) 6.29
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 6445.51
Total Assets 67666.73
Total Liabilities 67666.73
Total Equity 49479.83
Share Outstanding 2399334970
Price to Book Ratio 5.32
Return on Assets (%) 4.29
Return on Capital (%) 5.48
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 6487.55
Total Assets 68252.46
Total Liabilities 68252.46
Total Equity 49124.69
Share Outstanding 2399334970
Price to Book Ratio 3.46
Return on Assets (%) 5.51
Return on Capital (%) 6.64
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 338.39
Total Assets 41064.79
Total Liabilities 41064.79
Total Equity 23694.40
Share Outstanding 2399334970
Price to Book Ratio 16.41
Return on Assets (%) 6.96
Return on Capital (%) 8.23
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 421.28
Total Assets 40987.49
Total Liabilities 40987.49
Total Equity 23748.36
Share Outstanding 2399334970
Price to Book Ratio 9.93
Return on Assets (%) 4.12
Return on Capital (%) 5.39
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 534.96
Total Assets 40765.48
Total Liabilities 40765.48
Total Equity 24587.95
Share Outstanding 2399334970
Price to Book Ratio 8.93
Return on Assets (%) -0.24
Return on Capital (%) -0.34
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 360.98
Total Assets 43734.79
Total Liabilities 43734.79
Total Equity 26938.47
Share Outstanding 2399334970
Price to Book Ratio 5.32
Return on Assets (%) 1.92
Return on Capital (%) 2.47
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 654.78
Total Assets 38410.33
Total Liabilities 38410.33
Total Equity 24396.22
Share Outstanding 2399334970
Price to Book Ratio 3.46
Return on Assets (%) 8.36
Return on Capital (%) 10.65
Particulars MAR 2024 (Values in Cr)
Net Income 11087.89
Cash from Operations 13704.42
Cash from Investing -690.20
Cash from Financing -6710.16
Net change in Cash 4734.62
Free Cash Flow 15906.23
Particulars MAR 2023 (Values in Cr)
Net Income 9408.43
Cash from Operations 6469.17
Cash from Investing -7943.68
Cash from Financing 2376.07
Net change in Cash -608.28
Free Cash Flow 8554.75
Particulars MAR 2022 (Values in Cr)
Net Income 4481.32
Cash from Operations 8015.32
Cash from Investing -5724.74
Cash from Financing -5193.46
Net change in Cash -1933.66
Free Cash Flow 9510.36
Particulars MAR 2021 (Values in Cr)
Net Income 2799.37
Cash from Operations 7173.31
Cash from Investing 536.22
Cash from Financing -5980.48
Net change in Cash 726.11
Free Cash Flow 8343.44
Particulars MAR 2020 (Values in Cr)
Net Income 5009.59
Cash from Operations 7900.68
Cash from Investing -2588.84
Cash from Financing -5715.14
Net change in Cash -1749.21
Free Cash Flow 9442.68
Particulars MAR 2024 (Values in Cr)
Net Income 3449.65
Cash from Operations 49.45
Cash from Investing -262.91
Cash from Financing 473.95
Net change in Cash -81.38
Free Cash Flow 798.69
Particulars MAR 2023 (Values in Cr)
Net Income 1741.05
Cash from Operations 939.07
Cash from Investing -705.17
Cash from Financing 169.31
Net change in Cash -28.78
Free Cash Flow 1901.50
Particulars MAR 2022 (Values in Cr)
Net Income 306.86
Cash from Operations 5476.82
Cash from Investing -2702.10
Cash from Financing -4870.85
Net change in Cash 63.41
Free Cash Flow 6326.71
Particulars MAR 2021 (Values in Cr)
Net Income 855.57
Cash from Operations -178.84
Cash from Investing 1463.81
Cash from Financing -999.73
Net change in Cash 47.57
Free Cash Flow 629.23
Particulars MAR 2020 (Values in Cr)
Net Income 3253.00
Cash from Operations 1642.90
Cash from Investing 1479.29
Cash from Financing -2871.15
Net change in Cash -86.01
Free Cash Flow 2214.71

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 1670.90
  • 26 Days 1667.70
  • 10 Days 1653.30
  • 50 Days 1703.50
  • 12 Days 1651.70
  • 100 Days 1735.00
  • 20 Days 1658.20
  • 200 Days 1697.60

Sun Pharmaceutical Ind L Future

Future: Price

27 Mar
1737.70
24 Apr
1748.05
29 May
1753.50
25 May
0 100 200 300 400 500 600

Discount/Premium

27 Mar
-0.90
24 Apr
9.45
29 May
14.90
25 May
0 1 2 3 4 5 6 7

Active Calls

1740.0
4960
1720.0
4844
1760.0
2796
25 May
0 500 1000 1500 2000 2500 3000

Active Puts

1700.0
4453
1720.0
4387
1680.0
3418
25 Jul
0 500 1000 1500 2000 2500

Sun Pharmaceutical Ind L Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Stock Holding

View Live Stock Screeners

arrow-right

Holding

Public
8.92
Promoter Holdings
54.47
FII
18.04
DII
18.54
Promoter Shares(Pledge Percentage)
0.69
Name Category Shares Shares%
Shanghvi Finance Private Limited Shareholding of Promoter and Promoter Group 9.67051732E8 40.3
Dilip.s.shanghvi Shareholding of Promoter and Promoter Group 2.30385155E8 9.6
Icici Prudential Value Discovery Fund Public Shareholding 7.8229397E7 3.26
Life Insurance Corporation Of India Public Shareholding 7.0297545E7 2.93
Sbi Nifty 50 Etf Public Shareholding 5.2481228E7 2.19
Aditya Medisales Limited Shareholding of Promoter and Promoter Group 4.015396E7 1.67
Raksha S.valia Shareholding of Promoter and Promoter Group 2.8830352E7 1.2
Nps Trust- A/c Hdfc Pension Fund Management Limited Scheme E - Tier I Public Shareholding 2.8261351E7 1.18
Hdfc Trustee Company Ltd. A/c Hdfc Balanced Advantage Fund Public Shareholding 2.6944619E7 1.12
Lakshdeep Investments & Finance (p) Ltd. Public Shareholding 2.4418497E7 1.02
Government Pension Fund Global Public Shareholding 2.421442E7 1.01
Sudhir V. Valia Shareholding of Promoter and Promoter Group 1.4345019E7 0.6
Unimed Investments Limited Shareholding of Promoter and Promoter Group 1.040085E7 0.43
Vibha Dilip Shanghvi Shareholding of Promoter and Promoter Group 8840280.0 0.37
Vidhi Dilip Shanghvi Shareholding of Promoter and Promoter Group 2822427.0 0.12
Aalok Dilip Shanghvi Shareholding of Promoter and Promoter Group 2877280.0 0.12
Shanghvi Family & Friends Benefit Trust Shareholding of Promoter and Promoter Group 1276774.0 0.05
Gujarat Sun Pharmaceutical Industries Pvt Ltd Shareholding of Promoter and Promoter Group 14362.0 0.0
Sanghvi Properties Private Limited Shareholding of Promoter and Promoter Group 15479.0 0.0
Flamboyawer Finance Private Limited Shareholding of Promoter and Promoter Group 20865.0 0.0
Kumud Shantilal Shanghvi Shareholding of Promoter and Promoter Group 100000.0 0.0

Sun Pharmaceutical Ind L

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2024-02-09 8.5 Interim 2024-02-09 Equity shares 2023-07-28 4.0 Final 2023-07-28 Equity shares 2023-02-08 7.5 Interim 2023-02-08 Equity shares 2022-08-19 3.0 Final 2022-08-22 Equity shares 2022-02-09 7.0 Interim 2022-02-10 Equity shares 2021-08-23 2.0 Final 2021-08-25 Equity shares 2021-02-09 5.5 Interim 2021-02-10 Equity shares 2020-08-19 1.0 Final 2020-08-21 Equity shares 2020-02-17 3.0 Interim 2020-02-18 Equity shares 2019-08-20 2.75 Final 2019-08-22 Equity shares 2018-09-17 2.0 Final 2018-09-19 Equity shares 2017-09-18 3.5 Final 2017-09-20 Equity shares 2016-09-08 1.0 Final 2016-09-10 Equity shares 2015-10-21 3.0 Final 2015-10-24 Equity shares 2014-09-11 1.5 Final 2014-09-13 Equity shares 2013-09-19 2.5 Final 2013-09-23 Equity shares 2012-08-14 4.25 Interim 2012-08-16 Equity shares 2011-09-02 3.5 Final 2011-09-06 Equity shares 2010-09-09 13.75 Final 2010-09-14 Equity shares 2009-08-21 13.75 Final 2009-08-25 Equity shares 2008-08-25 10.5 Final 2008-08-27 Equity shares 2007-03-15 6.75 Final 2007-03-16 Equity shares 2005-09-19 0.0 Final 2005-09-21 Equity shares

Sun Pharmaceutical Industries Ltd Overview

Sun Pharmaceutical Industries Ltd, headquartered in India, is a global frontrunner in the pharmaceutical sector, holding the title of the largest pharmaceutical company in India. Since its establishment in 1981, Sun Pharma has dedicated itself to manufacturing, developing, and marketing an extensive array of branded and generic formulations along with Active Pharmaceutical Ingredients (APIs). The company showcases a diverse product portfolio targeting various chronic and acute treatments, available in forms ranging from injectables to capsules. With significant achievements like being the 11th largest in the US generics market as of September 2023, and leading the Indian branded generics market, Sun Pharma continues to expand its global footprint across emerging and developed markets, including strategic acquisitions to enhance its market position. It operates around 43 manufacturing facilities worldwide and is distinguished for its comprehensive R&D capabilities, focusing on specialty/complex products development. The company's international presence is marked by a sales force of approximately 2,200 representatives, selling products in about 80 countries with a focus on areas like dermatology, ophthalmology, and onco-dermatology. Through strategic acquisitions and a focus on R&D, Sun Pharma has solidified its standing as a pivotal player in the global pharmaceutical industry, combining extensive manufacturing capabilities with a robust product portfolio to address diverse medical needs.

Sun Pharma share result highlights

In the second quarter of fiscal year 2024-25, Sun Pharmaceutical Industries Ltd. reported a consolidated net profit of ₹3,040 crore, marking a 28% increase from ₹2,375 crore in the same period the previous year. Revenue from operations rose by 9% year-on-year to ₹13,291 crore, surpassing market estimates. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) grew 24% year-on-year to ₹3,939 crore, with a margin of 29.6%. Formulation sales in India increased 11% year-on-year to ₹4,265 crore, representing 32% of total sales. These robust financial results have positively influenced the Sun Pharma share price, reflecting increased investor confidence.

Sun Pharma share annual reports

The 2023-24 annual report of Sun Pharmaceutical Industries Ltd. provides comprehensive insights into its financial performance and strategic initiatives. The company achieved a total income of ₹45,000 crore, registering a growth of 5% from the previous year. The report highlights Sun Pharma's focus on expanding its product portfolio, enhancing operational efficiency, and implementing cost optimisation measures. These efforts have contributed to a stable Sun Pharma share price by showcasing the company's commitment to growth and profitability.

Sun Pharma share dividend

For the fiscal year 2023-24, Sun Pharmaceutical Industries Ltd. declared a total dividend of ₹12 per share, reflecting its commitment to returning value to shareholders. This consistent dividend payout, supported by strong financial performance, has positively impacted the Sun Pharma share price by enhancing investor confidence.

Learn More About Stocks

About Sun Pharmaceutical Ind L

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by Sun Pharmaceutical Ind L

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

Invest
investment-card-icon

IPOs

Your gateway to future financial opportunities

Invest
investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

Invest
investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

Invest
investment-card-icon

Frequently Asked Questions

What is the Share Price of Sun Pharmaceuticals Industries Ltd?

Answer Field

The share price of Sun Pharmaceuticals Industries Ltd for NSE is ₹ 1738 and for BSE is ₹ 1738.05.

What is the Market Cap of Sun Pharmaceuticals Industries Ltd?

Answer Field

The market cap of Sun Pharmaceuticals Industries Ltd for NSE is ₹ 41,70,04.40 Cr. and for BSE is ₹ 41,70,16.40 Cr. as of now.

What is the 52 Week High and Low of Sun Pharmaceuticals Industries Ltd?

Answer Field

The 52 Week High and Low of Sun Pharmaceuticals Industries Ltd for NSE is ₹ 1960.35 and ₹ 1377.20 and for BSE is ₹ 1960.20 and ₹ 1376.75.

How to Buy Sun Pharmaceuticals Industries Ltd share?

Answer Field

You can trade in Sun Pharmaceuticals Industries Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Sun Pharmaceuticals Industries Ltd?

Answer Field

The 1 year returns on the stock has been 8.46%.

What is the Current Share Price of Sun Pharmaceuticals Industries Ltd?

Answer Field

Sun Pharmaceuticals Industries Ltd share price is for NSE ₹ 1738 & for BSE ₹ 1738.05 as on Mar 18 2025 02:06 PM.

What is the Market Cap of Sun Pharmaceuticals Industries Ltd Share?

Answer Field

The market cap of Sun Pharmaceuticals Industries Ltd for NSE ₹ 41,70,04.40 & for BSE ₹ 41,70,16.40 as on Mar 18 2025 02:06 PM.

What is the P/E Ratio of Sun Pharmaceuticals Industries Ltd Share?

Answer Field

As on Mar 18 2025 02:06 PM the price-to-earnings (PE) ratio for Sun Pharmaceuticals Industries Ltd share is 129.94.

What is the PB ratio of Sun Pharmaceuticals Industries Ltd Share?

Answer Field

As on Mar 18 2025 02:06 PM, the price-to-book (PB) ratio for Sun Pharmaceuticals Industries Ltd share is 98.33.

How to Buy Sun Pharmaceuticals Industries Ltd Share on Bajaj Broking App?

Answer Field

To buy Sun Pharmaceuticals Industries Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Sun Pharmaceuticals Industries Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Popular FAQs

1. Who is the CEO of Sun Pharma Ltd?

As of November 2024, the Managing Director of Sun Pharmaceutical Industries Ltd. is Mr. Dilip Shanghvi. He oversees the company's operations and strategic initiatives, influencing the Sun Pharma share price through effective leadership and business expansion.

 

2. When was Sun Pharma Ltd established?

Sun Pharmaceutical Industries Ltd. was established in 1983. Over the decades, it has grown into one of India's leading pharmaceutical companies, impacting the Sun Pharma share price through its extensive operations and market presence.

 

3. What factors influence Sun Pharma Ltd share price fluctuations?

The Sun Pharma share price is influenced by various factors, including the company's financial performance, expansion of product portfolios, regulatory developments, and broader economic conditions. Additionally, market demand for pharmaceutical products, competition, and research and development outcomes play significant roles in determining share price movements.

 

4. Is Sun Pharma debt free?

No, Sun Pharmaceutical Industries Ltd. is not entirely debt-free. The company utilises debt financing to fund its capital-intensive projects and expansion plans. However, it maintains a balanced debt-to-equity ratio, ensuring financial stability and the ability to meet its obligations without adversely affecting the Sun Pharma share price.

 

5. What is the CAGR of Sun Pharma share?

Over the past five years, the Compound Annual Growth Rate (CAGR) of Sun Pharma shares has been approximately 10%. This indicates a steady growth in the Sun Pharma share price, reflecting the company's consistent financial performance and strategic initiatives.

 

6. How has the Sun Pharma share price performed over the past year?

Over the past year, the Sun Pharma share price has experienced fluctuations influenced by market conditions and company performance. As of November 2024, the share price has shown a modest increase compared to the same period last year, reflecting investor confidence in the company's strategic direction and financial health.

 

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download
9 lakh+ Users
icon-with-text
4.3+ App Rating
icon-with-text
4 Languages
icon-with-text
₹4300+ Cr MTF Book
icon-with-text
Open Demat Account

TRENDING CALCULATORS AND STOCKS ON BAJAJ BROKING

Popular Stock

top-popular-on-bfsl

POPULAR STOCKS: Tata Motors Share Price Infosys Share Price IRFC Share Price SBI Card Share Price Cipla Share Price NBCC Share Price IDFC First Bank Share Price IRCTC Share Price PNB Share Price Zomato Share Price Vodafone Idea Share Price Axis Bank Share Price JSW Steel Share Price Bandhan Bank Share Price SBI Share Price Tata Steel Share Price ONGC Share Price Ashok Leyland Share Price Paytm Share Price Subex Share Price DLF Share Price Reliance Share Price HDFC Bank Share Price Suzlon Share Price IOC Share Price HUL Share Price Asian Paints Share Price Bank Of Baroda Share Price ITC Share Price TCS Share Price HFCL Share Price Icici Bank Share Price Tata Chemicals Share Price CDSI Share Price MRF Share Price Tata Power Share Price Adani Green share price BPCL Share Price Vedanta Share Price Dmart Share Price Hindalco Share Price LIC Share Price SAIL Share Price Adani Port Share Price IEX Share Price Nalco Share Price L&T Share Price Adani Power Share Price BHEL Share Price Bajaj Finance Share Price Canara Bank Share Price Indusind Bank Share Price Gail Share Price Yes Bank Share Price Wipro Share Price Happiest Minds Share Price Coal India Share Price Maruti Share Price Reliance Power Share Price

 

INDIAN INDICES: Nifty 50 Share Price SENSEX Share Price Nifty Next 50 Share Price BSE100 Share Price Nifty Bank Share Price LRGCAP Share Price Nifty 100 Share Price MIDCAP Share Price Nifty 200 Share Price SMLCAP Share Price Nifty 500 Share Price BSE500 Share Price Nifty Midcap 50 Share Price ALLCAP Share Price NIFTY SMLCAP 50 Share Price BSE200 Share Price India VIX Share Price BSEIPO Share Price

ATTENTION INVESTORS:

“Investments in securities market are subject to market risk, read all the scheme related documents carefully before investing."

"Prevent Unauthorized transactions in your Trading/Demat Account. Update your mobile numbers/email IDs with your stock brokers/Depository Participant. Receive alerts/information of your transaction/all debit and other important transactions in your Trading/ Demat Account directly from Exchange/CDSL/NSDL at the end of the day. Issued in the interest of investors."

" We collect, retain, and use your contact information for legitimate business purposes only, to contact you and to provide you information & latest updates regarding our products & services."  

"KYC...

loader